12 Results for "

pfizer cancerogeno alc 0315

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "pfizer cancerogeno alc 0315" in MCE Product Catalog:

46
46 Cited Publications
Cat. No.: HY-138170
CAS No.: 2036272-55-4
Purity:  99.81%
Target:  

Liposome SARS-CoV

Research Areas:  

Infection

ALC-0315 is an ionisable aminolipid that is responsible for mRNA compaction and aids mRNA cellular delivery and its cytoplasmic release through suspected endosomal destabilization. ALC-0315 can be used to form lipid nanoparticle (LNP) delivery vehicles. Lipid-Nanoparticles have been used in the research of mRNA COVID-19 vaccine .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-19193
CAS No.: 158081-99-3
Synonyms: pfizer 105696
Target:  

Leukotriene Receptor

Research Areas:  

Inflammation/Immunology

CP-105696 is a potent and selective Leukotriene B4 Receptor antagonist, with an IC50 of 8.42 nM.
loading...
    loading...
Cat. No.: HY-142977
CAS No.: 1849616-54-1
Purity:  92.80%
Target:  

Drug Intermediate

Research Areas:  

Others

6-Oxohexyl 2-hexyldecanoate, 80% (ELSD) is an intermediate in the synthesis of ALC-0315. 6-Oxohexyl 2-hexyldecanoate, 80% (ELSD) can be used in research on drug delivery, such as mRNA delivery .
loading...
    loading...
Cat. No.: HY-138170GL
CAS No.: 2036272-55-4
ALC-0315 (GMP Like) is ALC-0315 (HY-138170) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. ALC-0315 is an ionisable aminolipid that is responsible for mRNA compaction and aids mRNA cellular delivery and its cytoplasmic release through suspected endosomal destabilization. ALC-0315 can be used to form lipid nanoparticle (LNP) delivery vehicles. Lipid-Nanoparticles have been used in the research of mRNA COVID-19 vaccine .
loading...
    loading...
Cat. No.: HY-173292
CAS No.: 2036273-14-8
Target:  

Liposome

Research Areas:  

Others

ALC-0315 analogue-4 is an ALC-0315 analog used in drug delivery.
loading...
    loading...
Cat. No.: HY-175049
CAS No.: 3117157-42-0
Target:  

Endogenous Metabolite

Research Areas:  

Others

ALC-0315 N-oxide is an impurity of ALC-0315 ( HY-138170). ALC-0315 is an ionisable aminolipid for mRNA delivery .
loading...
    loading...
Cat. No.: HY-172329
CAS No.: 3112713-48-8
Target:  

Liposome

Research Areas:  

Others

Q1-ALC-0315 iodide is a cationic quaternary ammonium lipid derivative of the ionizable cationic lipid ALC-0315 (HY-138170). Q1-ALC-0315-based LNPs can be used for lung-targeted mRNA delivery, which demonstrates high-performing firefly luciferase protein expression in the lungs .
loading...
    loading...
Cat. No.: HY-W800777
CAS No.: 2795212-31-4
Target:  

Liposome

Research Areas:  

Cancer

6-(3-Hydroxypropylamino)hexyl 2-hexyldecanoate is an ionizable lipid which can be used to make ALC-0315. The lipid has an ester bond adjacent to C6 relative to the amine nitrogen. The introduction of ester linkages can improve the clearance of the lipid in the liver.
loading...
    loading...
Cat. No.: HY-172332
CAS No.: 3097638-09-7
Target:  

Liposome NF-κB

Research Areas:  

Inflammation/Immunology Cancer

H1L1A1B3 is an ionizable cationic lipid used in the formation of lipid nanoparticles (LNPs) for the delivery of circular RNA (circRNA). H1L1A1B3-LNPs demonstrates a fourfold increase in circRNA transfection efficiency in lung cancer cells over ALC-0315 (HY-138170). H1L1A1B3 can activate the NF-κB/IRF immune pathways .
loading...
    loading...
Cat. No.: HY-W1130405
CAS No.: 2036273-20-6
Target:  

Liposome

Research Areas:  

Metabolic Disease

((1-Hydroxybutan-2-yl)azanediyl)bis(hexane-6,1-diyl) bis(2-hexyldecanoate) is an ionizable cationic lipid (pKa = 4.67) and a derivative of ALC-0315).
loading...
    loading...
Cat. No.: HY-L920
24,816 compounds
With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. The CNS MPO (Multi-Parameter Optimization) score is a widely recognized algorithm in medicinal chemistry. Developed by Pfizer, this method is based on an analysis of approved CNS drugs and their interior CNS drug candidates, establishing the CNS MPO rules. It incorporates six key physicochemical properties (ClogP, ClogD, MW, TPSA, HBD, and pKa) to prospectively optimize CNS drug attributes—such as high blood-brain barrier (BBB) permeability, low P-gp efflux liability, low metabolic clearance, and high safety—thereby improving the clinical success rate of CNS drug candidates. The CNS MPO compound library is a collection of compounds with CNS MPO scores greater than 5, specifically designed for CNS drug discovery.
  • 1